WO2012082765A3 - Methods for decreasing body weight and treating diabetes - Google Patents

Methods for decreasing body weight and treating diabetes Download PDF

Info

Publication number
WO2012082765A3
WO2012082765A3 PCT/US2011/064690 US2011064690W WO2012082765A3 WO 2012082765 A3 WO2012082765 A3 WO 2012082765A3 US 2011064690 W US2011064690 W US 2011064690W WO 2012082765 A3 WO2012082765 A3 WO 2012082765A3
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
methods
hif1α
inhibitor
treating diabetes
Prior art date
Application number
PCT/US2011/064690
Other languages
French (fr)
Other versions
WO2012082765A2 (en
Inventor
Frank J. Gonzalez
Changtao Jiang
Original Assignee
The United State Of America. As Represented By The Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United State Of America. As Represented By The Secretary Department Of Health And Human Services filed Critical The United State Of America. As Represented By The Secretary Department Of Health And Human Services
Publication of WO2012082765A2 publication Critical patent/WO2012082765A2/en
Publication of WO2012082765A3 publication Critical patent/WO2012082765A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Abstract

Disclosed herein are methods of treating diabetes (e.g., increasing glucose tolerance, reducing insulin resistance, and decreasing serum lipids) and/or reducing body weight (e.g., treating overweight or obesity) including administering a therapeutically effective amount of a composition including an inhibitor of hypoxia- inducible factor la (HIF1α) to a subject with diabetes or a subject in need of reduction of body weight. The HIF1α inhibitor can be administered in combination with a pharmaceutically acceptable carrier. In some examples, the HIF1α inhibitor is administered orally.
PCT/US2011/064690 2010-12-16 2011-12-13 Methods for decreasing body weight and treating diabetes WO2012082765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42393610P 2010-12-16 2010-12-16
US61/423,936 2010-12-16

Publications (2)

Publication Number Publication Date
WO2012082765A2 WO2012082765A2 (en) 2012-06-21
WO2012082765A3 true WO2012082765A3 (en) 2012-10-11

Family

ID=45444736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/064690 WO2012082765A2 (en) 2010-12-16 2011-12-13 Methods for decreasing body weight and treating diabetes

Country Status (1)

Country Link
WO (1) WO2012082765A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503394A (en) 2012-10-26 2016-02-04 エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． Compositions and methods for selective delivery of oligonucleotide molecules to cell types
WO2020225427A1 (en) 2019-05-09 2020-11-12 Teresa Pereira Treatment of diabetes
JP2023538612A (en) * 2020-08-18 2023-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for diabetes treatment and beta cell regeneration

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
WO2006016143A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
WO2006047485A2 (en) * 2004-10-25 2006-05-04 Henry M. Jackson Foundation Methods for lowering hif-1 mediated gene expression
US20070253904A1 (en) * 2004-07-15 2007-11-01 Jenny Gunton Methods of treating diabetes
WO2008093086A1 (en) * 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2009019656A1 (en) * 2007-08-07 2009-02-12 Piramal Life Sciences Limited Pyridyl derivatives, their preparation and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR100201352B1 (en) 1995-03-16 1999-06-15 성재갑 Single shot vaccine formulation
US6921496B2 (en) 2000-03-20 2005-07-26 Massachusetts Institute Of Technology Inorganic particle conjugates
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
ES2268068T3 (en) 2001-03-30 2007-03-16 The Usa, Represented By The Secretary, Dept. Of Health And Human Services National Institutes Health DERIVED FROM GELDANAMYCIN USEFUL FOR THE TREATMENT OF CANCER.
US7081489B2 (en) 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
HUE037352T2 (en) 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As Oligomeric compounds for the modulation of hif-1alpha expression
US20040087556A1 (en) 2002-11-06 2004-05-06 Lynn Kirkpatrick N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
WO2004064751A2 (en) 2003-01-16 2004-08-05 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
CA2513398C (en) 2003-01-31 2013-09-10 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
WO2006052285A2 (en) 2004-05-13 2006-05-18 The Trustees Of Columbia University In The City Of New York Polymeric nanoparticles and nanogels for extraction and release of compounds
CA2587173C (en) 2004-11-09 2016-09-06 Santaris Pharma A/S Potent lna oligonucleotides for the inhibition of hif-1a expression
US7342048B2 (en) 2005-04-28 2008-03-11 Nipro Corporation Bioabsorbable pharmaceutical formulation
WO2006122127A1 (en) 2005-05-10 2006-11-16 Naomi Balaban Compositions for administering rnaiii-inhibiting peptides
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
AU2009321723A1 (en) 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of HIF-1 protein accumulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20070253904A1 (en) * 2004-07-15 2007-11-01 Jenny Gunton Methods of treating diabetes
WO2006016143A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
WO2006047485A2 (en) * 2004-10-25 2006-05-04 Henry M. Jackson Foundation Methods for lowering hif-1 mediated gene expression
WO2008093086A1 (en) * 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2009019656A1 (en) * 2007-08-07 2009-02-12 Piramal Life Sciences Limited Pyridyl derivatives, their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANG CHANGTAO ET AL: "Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice.", DIABETES OCT 2011 LNKD- PUBMED:21873554, vol. 60, no. 10, October 2011 (2011-10-01), pages 2484 - 2495, XP009161927, ISSN: 1939-327X *

Also Published As

Publication number Publication date
WO2012082765A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
JP2014528474A5 (en)
WO2011107750A3 (en) Delayed prolonged drug delivery
WO2011107755A3 (en) Immediate/delayed drug delivery
IL208992A (en) Use of a pharmaceutically active h2 relaxin in the manufacture of medicaments for treating dyspnea associated with acute heart failure and acute decompensated heart failure
WO2011127304A3 (en) Methods of treating an overweight subject
IN2014KN00996A (en)
JP2012529485A5 (en) Compositions and methods for the prevention and treatment of red blood cell coagulation
WO2012068274A8 (en) Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
JP2012520866A5 (en)
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2012142413A3 (en) Nitrite compositions and uses thereof
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL223434A (en) Use of a n-acetylneuraminic acid, a precursor of nacetylneuraminic acid or a combination thereof in the preparation of a medicament for treatment of diabetic conditions and a method of determining the status of a subject with respect to nephrotic syndrome or a diabetic condition
WO2012082765A3 (en) Methods for decreasing body weight and treating diabetes
Rafraf et al. Effect of l-carnitine supplementation in comparison with moderate aerobic training on insulin resistance and anthropometric indices in obese women
MX2012010520A (en) Antioxidant composition for reducing oxidative stress ascribable to the treatment with hormonal contraceptive drugs.
WO2009005046A1 (en) Therapeutic agent for ulcerative colitis comprising mizoribine
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2013121300A3 (en) Methods for treating psoriasis and vascular inflammation
WO2012047628A3 (en) Methods of managing blood sugar levels and compositions related thereto
WO2008105533A1 (en) Adiponectin secretion-stimulating agent comprising capsinoid compound
JP2011105610A5 (en)
WO2012091425A3 (en) Composition containing a 4-hydroxytamoxifen analog or the pharmaceutically acceptable salts thereof as an active ingredient for preventing or treating diseases associated with metabolic syndrome
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804860

Country of ref document: EP

Kind code of ref document: A2